Emily Bodnar’s ranking relies within the anticipation of important milestones for Agenus in the approaching year, significantly the likely filing of a Biologics License Application (BLA) for their direct drug prospect, botensilimab (bot). Agenus has dosed over 900 individuals with bot across a variety of stable tumors, demonstrating a determinati